AR087544A2 - Cristales de aripiprazol anhidro b - Google Patents

Cristales de aripiprazol anhidro b

Info

Publication number
AR087544A2
AR087544A2 ARP120102986A ARP120102986A AR087544A2 AR 087544 A2 AR087544 A2 AR 087544A2 AR P120102986 A ARP120102986 A AR P120102986A AR P120102986 A ARP120102986 A AR P120102986A AR 087544 A2 AR087544 A2 AR 087544A2
Authority
AR
Argentina
Prior art keywords
crystals
exhibit
heating rate
endothermic peak
low hygroscopicity
Prior art date
Application number
ARP120102986A
Other languages
English (en)
Inventor
Bando Takuji
Aoki Satoshi
Kawasaki Junichi
Ishigami Makoto
Taniguchi Youichi
Yabuuchi Tsuyoshi
Fujimoto Kiyoshi
Nishioka Yoshihiro
Kobayashi Noriyuki
Fujimura Tsutomu
Takahashi Masanori
Abe Kaoru
Nakagawa Tomonori
Shinhama Koichi
Utsumi Naoto
Tominaga Michiaki
Oi Yoshihiro
Yamada Shohei
Tomikawa Kenji
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36049773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087544(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR087544A2 publication Critical patent/AR087544A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente provee cristales de Aripiprazol anhidro B que tienen baja higroscopicidad, donde dicha baja higroscopicidad es un contenido de humedad del 0,40% o menos luego de colocar dicha sustancia medicinal durante 24 horas en un secador, mantenido a una temperatura de 60ºC y un nivel de humedad del 100% y donde dichos Cristales de Aripiprazol anhidro B, tienen un espectro de difracción de rayos X en polvos que tienen picos característicos en 2q: 11,0º, 16,6º, 19,3º, 20,3º y 22,1º; tienen bandas de absorción infrarroja particulares en 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960 y 779 cm⁻¹ en el espectro IR (KBr), y exhiben un pico endotérmico cercano a aproximadamente los 141,5ºC en un análisis térmico diferencial / termogravimétrico (velocidad de calentamiento 5ºC/min.), que exhiben un pico endotérmico cercano a aproximadamente los 140,7ºC en la calorimetría diferencial de barrido (velocidad de calentamiento 5ºC/min.).
ARP120102986A 2001-09-25 2012-08-15 Cristales de aripiprazol anhidro b AR087544A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
AR087544A2 true AR087544A2 (es) 2014-04-03

Family

ID=36049773

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP090103228A AR073111A2 (es) 2001-09-25 2009-08-21 La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ARP100102387A AR077635A2 (es) 2001-09-25 2010-07-05 Hidrato a de aripiprazol
ARP120102986A AR087544A2 (es) 2001-09-25 2012-08-15 Cristales de aripiprazol anhidro b

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP090103228A AR073111A2 (es) 2001-09-25 2009-08-21 La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ARP100102387A AR077635A2 (es) 2001-09-25 2010-07-05 Hidrato a de aripiprazol

Country Status (21)

Country Link
EP (1) EP3081216A1 (es)
KR (2) KR100530731B1 (es)
CN (12) CN103751118A (es)
AR (3) AR073111A2 (es)
CA (1) CA2713466C (es)
CL (1) CL2010000405A1 (es)
CY (4) CY1110208T1 (es)
DK (1) DK1925308T3 (es)
ES (1) ES2596354T3 (es)
HK (14) HK1203060A1 (es)
IL (3) IL204707A (es)
LT (1) LT1925308T (es)
MY (1) MY138669A (es)
NO (1) NO337844B1 (es)
PE (1) PE20030445A1 (es)
PH (1) PH12014500782A1 (es)
PL (7) PL219565B1 (es)
PT (1) PT1925308T (es)
RU (1) RU2279429C2 (es)
SI (1) SI1927357T1 (es)
TW (2) TWI318572B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR102128883B1 (ko) * 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3638447B2 (ja) * 1998-09-10 2005-04-13 積水ハウス株式会社 笠木取付金具および笠木取付構造
GB9930061D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Quinolone compounds for use in treating viral infections
US6906072B1 (en) * 2000-01-20 2005-06-14 Eisai Co., Ltd. Piperazine compound and pharmaceutical composition containing the compound
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
JP2002193915A (ja) * 2000-12-28 2002-07-10 Otsuka Pharmaceut Co Ltd ベンゼンスルフォナート化合物

Also Published As

Publication number Publication date
CN103751093A (zh) 2014-04-30
CN103755632A (zh) 2014-04-30
SI1927357T1 (sl) 2010-09-30
HK1136959A1 (en) 2010-07-16
CY1110244T1 (el) 2015-01-14
PL393598A1 (pl) 2011-04-26
CN103751118A (zh) 2014-04-30
PL393601A1 (pl) 2011-04-26
HK1136960A1 (en) 2010-07-16
CN103755632B (zh) 2016-06-29
PL417178A1 (pl) 2016-07-04
PL393603A1 (pl) 2011-04-26
PH12014500782A1 (en) 2018-09-10
AR077635A2 (es) 2011-09-14
EP3081216A1 (en) 2016-10-19
NO337844B1 (no) 2016-06-27
IL204707A (en) 2016-06-30
HK1136961A1 (en) 2010-07-16
IL225902A0 (en) 2013-06-27
RU2004126636A (ru) 2006-02-10
MY138669A (en) 2009-07-31
HK1129891A1 (en) 2009-12-11
IL204707A0 (en) 2010-11-30
PL393607A1 (pl) 2011-03-14
KR20030060871A (ko) 2003-07-16
CN103751119A (zh) 2014-04-30
CN104306337A (zh) 2015-01-28
CA2713466A1 (en) 2003-04-03
PT1925308T (pt) 2016-10-24
TWI332839B (en) 2010-11-11
NO20141193L (no) 2003-01-17
CA2713466C (en) 2012-01-03
HK1136958A1 (en) 2010-07-16
CN103191118A (zh) 2013-07-10
ES2596354T3 (es) 2017-01-09
HK1223043A1 (zh) 2017-07-21
CL2010000405A1 (es) 2010-10-15
PL230869B1 (pl) 2018-12-31
TW200942238A (en) 2009-10-16
KR100530731B1 (ko) 2005-11-23
CN105832677A (zh) 2016-08-10
KR20040053372A (ko) 2004-06-23
LT1925308T (lt) 2016-11-10
CN103288727A (zh) 2013-09-11
CN103288727B (zh) 2016-04-27
PL221536B1 (pl) 2016-04-29
HK1210468A1 (en) 2016-04-22
CY1110212T1 (el) 2015-01-14
IL234770A0 (en) 2014-11-30
CN104306374A (zh) 2015-01-28
HK1187048A1 (zh) 2014-03-28
PL219564B1 (pl) 2015-05-29
PE20030445A1 (es) 2003-07-26
HK1203059A1 (en) 2015-10-16
HK1092808A1 (en) 2007-02-16
HK1196128A1 (zh) 2014-12-05
PL393596A1 (pl) 2011-04-26
RU2279429C2 (ru) 2006-07-10
TWI318572B (en) 2009-12-21
KR100490222B1 (ko) 2005-05-18
PL221521B1 (pl) 2016-04-29
CN102579446A (zh) 2012-07-18
CY1110070T1 (el) 2015-01-14
HK1129889A1 (en) 2009-12-11
CN105267151A (zh) 2016-01-27
CY1110208T1 (el) 2015-01-14
PL393608A1 (pl) 2011-03-14
HK1203060A1 (en) 2015-10-16
HK1215397A1 (zh) 2016-08-26
PL219565B1 (pl) 2015-05-29
AR073111A2 (es) 2010-10-13
CN104945321A (zh) 2015-09-30
DK1925308T3 (en) 2016-12-12

Similar Documents

Publication Publication Date Title
AR056503A2 (es) SUSTANCIA MEDICINAL DE ARIPIRAZOL DE BAJA HIGROSCOPICIDAD Y PROCESO PARA LA PREPARACIoN DE LA MISMA
AR087544A2 (es) Cristales de aripiprazol anhidro b
BR9205870A (pt) Composiçoes compreendendo acidos 2-hidroxicarboxilicos e compostos relacionados e métodos para aliviar sinais de envelhecimento dermatologico.
Bruni et al. Characterization of ancient magnesian mortars coming from northern Italy
RU2328489C3 (ru) Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее получения
WO2016024434A1 (ja) 縮合１１員環化合物及びそれらを含有する農園芸用殺菌剤
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
WO2017138069A1 (ja) 殺菌性組成物
FI854069L (fi) Flyktig metallkomplex.
Koriem et al. Protective effect of extract against indomethacin-induced gastric ulcer in rats
CA2647346A1 (en) Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
EA200200875A1 (ru) Пролекарства производных имидазопиридина
WO2005090237A3 (fr) Procede de preparation d'un oxyde de lithium et de vanadium du type li (1+a) v308
JP2005523933A5 (es)
NZ514522A (en) Chemical compounds and their uses
KR101096784B1 (ko) 위 손상 예방 효과를 갖는 미네랄죽염 제조방법
Houshia et al. Assessment of the value of the antacid contents of selected palestinian plants
Brzyska et al. Properties and thermal decomposition in air atmosphere of complexes of Co (II), Ni (II) and Cu (II) with 2, 6-dichlorobenzoic acid
DK0812320T3 (da) Amorft piretanid, polymorfe former deraf, fremgangsmåde til fremstilling deraf og deres anvendelse
Saitoh et al. Carbon dioxide exchange over a Bornean tropical rainforest
Kim et al. Antibacterial compounds of the root barks of Cudrania tricuspidata
TH155176A (th) สารรักษาโรคชนิดแอริพิแพรโซลซึ่งดููดความชื้นต่ำและกรรมวิธีสำหรับการเตรียม ของสารรักษาโรคนี้
Rao et al. Synthesis and Spectral Studies of Lanthanide Metal Complexes of Furfural Isonicotinoylhydrazone
Refat et al. Mn (II), Co (II), Fe (III) And Cu (II) complexes of antihistaminic “fexofenadine” and amucolytic “carbocysteine” drugs: synthesis, spectroscopic and thermal studies
JPS55104627A (en) Preparation of drying agent

Legal Events

Date Code Title Description
FC Refusal
FC Refusal